All News

It is essential for patients who receive immune checkpoint inhibitors to actively communicate with their care teams when experiencing symptoms, an expert explained.

CURE® highlights some of the most significant lung cancer news of 2023 in honor of Lung Cancer Awareness Month.

An expert explained the different treatment options for patients with estrogen receptor-positive, HER2-negative breast cancer that has recently been diagnosed or has recurred.

An expert reflects on the recent FDA approval of adjuvant Opdivo for patients with stage 2B or 2C melanoma.

Sometimes after a diagnosis of cancer, plans and attending events can become elusive due to symptoms and treatments.

The Food and Drug Administration revised the existing approval of Keytruda, Herceptin and chemotherapy for patients with unresetable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.

Oncology telehealth services became more popular during the COVID-19 pandemic and remain to be important for patients with cancer, according to a recent survey.

This November, our country celebrates 76 years of Veteran’s Day, and we want to increase awareness of veterans with lung cancer in this special issue of CURE.

A cancer community creates support and care throughout a cancer experience.

Dr. Gene G. Finley spoke about current patient treatment obstacles as part of CURE’s ‘Speaking Out’ video series.

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.

U.S. veterans face exposures during military service and disparities at home.

Friendship means the world throughout a cancer experience.

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia.

This episode of the Cancer Horizons podcast features genitourinary oncologist Ulka Vaishampayan, MBBS, and is sponsored by Bristol Myers Squibb.

Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia.

Managing side effects from lung cancer treatment with dose reductions is an approach experts have been using more, even though some patients voice concerns about lowering a drug’s impact on the disease.

Can I be honest with you?

Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study.

CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.

Patients with extensive-stage small cell lung cancer responded well to the treatment of Trodelvy, according to preliminary results from a phase 2 trial.

My world turned upside down in April 2013 on the anniversary of my mother in laws death from metastatic breast cancer.

It is happening again.

When I was diagnosed with a rare cancer at the “stump” of my appendix, I was surprised, considering I had my appendix removed more than a decade ago.

Stephen Peck created a nonprofit that addressed the unique needs of men caring for someone with cancer.